Alvotech Moves Ahead On Higher-Concentration Humira Rival

 
• By Dave Wallace

Alvotech is moving ahead with developing its higher-concentration adalimumab biosimilar after completing enrollment in a European Phase III trial.

Enrollment
Enrollment Is Complete For Alvotech’s Phase III Trial • Source: Shutterstock

More from Biosimilars

More from Products